This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Low molecular weight heparin for acute ischaemic stroke

Authoring team

Low molecular weight heparin has been trialled for the treatment of acute ischaemic stroke:

  • 312 patients within 48 hours of onset of ischaemic stroke
  • randomised to 4100 U of LMWH once or twice daily or placebo
  • treated for 10 days
  • followed for 6 months

The rates of mortality or dependency at 6 months were:

  • 45% for the twice daily LMWH group
  • 52% for the once daily LMWH group
  • 65% for the placebo group

The rates of haemorrhagic transformation were the same.

Reference:

  • Kay, R. et al. (1995). Low-molecular-weight heparin for the treatment of acute ischemic stroke. NEJM, 333, 1588-93.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.